Response to Afatinib in a Common EGFR-Mutated Lung Adenocarcinoma with a Very Rare Combination of Compound Mutations.
作者信息
Satoh Hiroaki, Miyazaki Kunihiko, Sato Yoshiharu, Hizawa Nobuyuki
机构信息
Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba.
Division of Respiratory Medicine, Ryugasaki Saiseikai Hospital.
出版信息
Turk Thorac J. 2022 Sep;23(5):364-365. doi: 10.5152/TurkThoracJ.2022.22034.
Abstract
摘要
相似文献
1
Response to Afatinib in a Common EGFR-Mutated Lung Adenocarcinoma with a Very Rare Combination of Compound Mutations.阿法替尼对具有非常罕见复合突变组合的常见表皮生长因子受体（EGFR）突变型肺腺癌的反应
Turk Thorac J. 2022 Sep;23(5):364-365. doi: 10.5152/TurkThoracJ.2022.22034.
2
EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.表皮生长因子受体（EGFR）第18外显子E709_T710缺失并插入D突变的IV期肺腺癌，对阿法替尼有反应。
Lung Cancer. 2017 Jun;108:45-47. doi: 10.1016/j.lungcan.2017.02.023. Epub 2017 Mar 1.
3
The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study.阿法替尼与贝伐单抗联合用于未经治疗的EGFR突变型晚期肺腺癌：一项多中心观察性研究
Pharmaceuticals (Basel). 2020 Oct 23;13(11):331. doi: 10.3390/ph13110331.
4
Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.比较阿法替尼与吉非替尼或厄洛替尼对携带非经典表皮生长因子受体突变的晚期肺腺癌患者的疗效。
Lung Cancer. 2017 Aug;110:56-62. doi: 10.1016/j.lungcan.2017.06.007. Epub 2017 Jun 13.
5
Complete Response to Afatinib of an EGFR Exon 18 delE709_T710insD-Mutated Stage IV Lung Adenocarcinoma.EGFR外显子18 delE709_T710insD突变的IV期肺腺癌对阿法替尼完全缓解
Eur J Case Rep Intern Med. 2021 Aug 11;8(8):002749. doi: 10.12890/2021_002749. eCollection 2021.
6
Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series.阿法替尼治疗初治的伴有脑转移的EGFR突变型肺腺癌患者：病例系列
Medicine (Baltimore). 2015 Oct;94(41):e1739. doi: 10.1097/MD.0000000000001739.
7
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.阿法替尼治疗表皮生长因子受体突变的肺腺癌患者（LUX-Lung 2）：一项 2 期临床试验。
Lancet Oncol. 2012 May;13(5):539-48. doi: 10.1016/S1470-2045(12)70086-4. Epub 2012 Mar 26.
8
Successful Treatment of a Patient with Lung Adenocarcinoma Harboring Compound EGFR Gene Mutations, G719X and S768I, with Afatinib.阿法替尼成功治疗一例携带EGFR基因复合突变G719X和S768I的肺腺癌患者
Tokai J Exp Clin Med. 2020 Sep 20;45(3):113-116.
9
Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report.肺腺癌中携带 EGFR T751I759delinsS 突变的阿法替尼和奥希替尼治疗：一例报告。
Thorac Cancer. 2021 Dec;12(24):3429-3432. doi: 10.1111/1759-7714.14215. Epub 2021 Nov 2.
10
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations.阿法替尼治疗罕见 EGFR p.L747P 和 p.L747S 突变型肺腺癌有效。
Lung Cancer. 2019 Jul;133:103-109. doi: 10.1016/j.lungcan.2019.05.019. Epub 2019 May 17.
本文引用的文献
1
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.阿法替尼治疗具有罕见表皮生长因子受体（EGFR）突变的非小细胞肺癌：一个包含693例病例的数据库。
J Thorac Oncol. 2020 May;15(5):803-815. doi: 10.1016/j.jtho.2019.12.126. Epub 2020 Jan 10.
2
Selective identification of somatic mutations in pancreatic cancer cells through a combination of next-generation sequencing of plasma DNA using molecular barcodes and a bioinformatic variant filter.通过使用分子条形码对血浆DNA进行二代测序与生物信息变异过滤相结合的方法，对胰腺癌细胞中的体细胞突变进行选择性鉴定。
PLoS One. 2018 Feb 16;13(2):e0192611. doi: 10.1371/journal.pone.0192611. eCollection 2018.
3
High-fidelity target sequencing of individual molecules identified using barcode sequences: de novo detection and absolute quantitation of mutations in plasma cell-free DNA from cancer patients.使用条形码序列鉴定单个分子的高保真靶向测序：癌症患者血浆游离DNA中突变的从头检测和绝对定量。
DNA Res. 2015 Aug;22(4):269-77. doi: 10.1093/dnares/dsv010. Epub 2015 Jun 29.
4
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.阿法替尼对比基于顺铂的化疗用于 EGFR 突变阳性肺腺癌（LUX-Lung 3 和 LUX-Lung 6）：两项随机、III 期临床试验总生存数据的分析。
Lancet Oncol. 2015 Feb;16(2):141-51. doi: 10.1016/S1470-2045(14)71173-8. Epub 2015 Jan 12.
5
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.阿法替尼对比顺铂加吉西他滨用于治疗亚洲表皮生长因子受体突变阳性的晚期非小细胞肺癌患者的一线治疗（LUX-Lung 6）：一项开放标签、随机、III 期临床试验。
Lancet Oncol. 2014 Feb;15(2):213-22. doi: 10.1016/S1470-2045(13)70604-1. Epub 2014 Jan 15.
6
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.III 期研究阿法替尼或顺铂加培美曲塞治疗 EGFR 突变的转移性肺腺癌患者。
J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1.
Zotero 插件